RNA editing is an epitranscriptomic modification of emerging relevance to disease development and manifestations. ADAR1, which resides on human chromosome 1q21, is an RNA editor whose over-expression, either by interferon (IFN) induction or through gene amplification, is associated with increased editing and poor outcomes in Multiple Myeloma (MM). Here we explored the role of ADAR1 in the context of MM progression, by focusing on a group of 23 patients in the MMRF CoMMpass Study for which RNAseq and WES datasets exist for matched pre-and post-relapse samples. Our analysis reveals an acquisition of new DNA mutations on disease progression at specific loci surrounding the sites of ADAR associated (A-to-I) RNA editing. These analyses suggest that the RNA editing enzyme ADAR1 can function as a DNA mutator during Multiple Myeloma (MM) progression. These data imply that guide-targeted RNA editing has the capacity to generate specific mutational signatures at predetermined locations. More generally, these data suggest that a dual role of RNA editor and DNA mutator might be shared by other deaminases, such as APOBECs, so that DNA mutation might be the result of collateral damage on the genome by an editing enzyme whose primary job is to re-code the cognate transcript toward specific functional outcomes.
INTRODUCTION
The Adenosine Deaminase Acting on RNA (ADAR) family consists of two enzymes (ADAR1 and -2) with demonstrated deaminase activity and one (ADAR3) for which catalytic deamination activity has not been demonstrated, but which might have other functions (Valente and Nishikura, 2005; Gallo et al., 2017; Oakes et al., 2017; Mladenova et al., 2018) . The focus of this study, ADAR1, is ubiquitously expressed. ADAR1 deaminates Adenosine to Inosine (A-to-I), which is recognized by cellular machineries as a Guanosine (G). This molecular phenomenon is been used to generate an "index" (Alu Editing Index or AEI) that can be used comparatively to stage tumors (Bazak, Levanon and Eisenberg, 2014; Paz-Yaacov et al., 2015; Roth, Levanon and Eisenberg, 2019) . Recently, CRISPR/Cas screens revealed that tumors are vulnerable to ADAR1 loss, which coincides with a substantial interferon response, and with tumor cell death (Gannon et al., 2018) . But even in tumors where the IFN pathway is abrogated, loss of ADAR1 is still consequential, possibly because it reduces the informational heterogeneity of a tumor (Paz-Yaacov et al., 2015; Pecori et al, submitted) . These recent experiments have motivated a search for ADAR1 inhibitors as cancer therapeutics.
Here, we focus on Multiple Myeloma (MM), a malignant cancer of plasma cells (Laganà et al., 2018) . One of the common features of MM (occurring in roughly 40% of newly diagnosed patients) is the amplification of chromosome 1q21, which is associated with poor prognosis (Klein et al., 2010; Nemec et al., 2010; Chang et al., 2011) . The 1q21 locus is also the genomic location of ADAR1, and when this chromosomal fraction is amplified in MM, ADAR1 expression is increased, as is editing (Lazzari et al., 2017; Teoh et al., 2018) . Because of this link between 1q21 amplification and prognosis in MM, MM has been one of the tumors in which ADAR1 editing has been relatively well studied (Lazzari et al., 2017; Teoh et al., 2018) . A similar mechanism of ADAR1 upregulation by 1q amplification has also been described in breast cancer (Fumagalli et al., 2015) . Here we turn our attention to the role of ADAR1 in MM disease progression, and describe a new role for ADAR1, not only as an RNA editor but also as a DNA mutator.
RESULTS

ADAR1 expression in Multiple Myeloma is driven either by 1q amplification or by interferon
signaling. The amplification of 1q identifies a subclass of MM patients characterized by a more aggressive disease course and poor prognosis. The ADAR1 gene resides in 1q21 and previous studies have reported higher expression of ADAR1 in patients with 1q amplification and have shown worse progression-free (PFS) and overall survival (OS) in patients with high ADAR1 expression (Lazzari et al, 2017; Teoh et al, 2018) . We analyzed Whole-Genome Sequencing (WGS), Whole-Exome Sequencing (WES) and RNA-Seq data from 526 newly diagnosed MM patients in the MMRF CoMMpass study (https://research.themmrf.org/). Our analysis confirmed worse PFS and OS for patients with 1q copy number (CN) gain (>2 copies) ( Fig. 1A and Fig. S1A , CN>2 shown as ADAR+) and that ADAR1 expression was significantly higher for the ADAR+ patients (Wilcoxon Rank Sum Test p < 10 -3 ) ( Fig. 1B) . However, we also observed several patients with high expression of ADAR1 and no ADAR1 copy number gain (Fig. 1C) . Differential expression analysis revealed a significant enrichment of interferon-related pathways (IFN) in this group of patients (adj-p < 10 -7 ). These findings strongly suggest that ADAR1 overexpression is a key driver in MM, and this can be achieved either through 1q21 amplification or through IFN induction (and subsequent upregulation of the ADAR1 p150 isoform, which is an interferonstimulated gene (ISG) (George, Wagner and Samuel, 2005) . A similar situation has been reported in breast cancer as well (Fumagalli et al., 2015) .
Elevated ADAR1-mediated RNA editing (quantified with the Alu Editing Index or AEI) is strongly associated with poor patient survival. To quantify ADAR1-mediated A-to-I RNA editing in a sample-wise fashion, we calculated Alu Editing Index (AEI) for an extended set of 590 patients in the MMRF CoMMpass study. Our results showed that AEI is strongly correlated with ADAR1 global expression across the patient cohort ( Fig. 1D ) and that patients with high AEI had significantly lower PFS and OS ( Fig. S1B, Fig. 1E ). Furthermore, AEI could significantly discriminate between good and poor prognosis even within the group of patients with 1q gain (PFS: p=1.03x10 -5 , OS: p=4.08x10 -4 ), demonstrating that high RNA editing, as measured by AEI, can be an adverse prognostic factor independently of such alterations ( Fig. 1F, 1G) . Concordantly with the analysis of ADAR expression, pathway enrichment analysis revealed that patients with high AEI were characterized by up-regulation of interferon signaling, supporting the contribution of pro-inflammatory signaling to ADAR expression and activity, and by down-regulation of immunoglobulin genes and pathways that are relevant in MM, such as the unfolded protein response (UPR) and glycosylation ( Fig. S1C ).
ADAR1 as an RNA editor and as DNA mutator in Multiple Myeloma. We had previously noted that, within a cohort of patients at a specific disease stage, the list of known driver mutations at the population level was broadly similar with lists of ADAR edited sites per patient (this was true for DLBCL -Pecori et al, submitted; and similarly, for MM ( Figure S2 ). We therefore wondered whether ADAR1 was capable of not only editing RNA but also mutating DNA. Fundamentally this would be possible as the ubiquitous ADAR1 isoform p110 contains Z-DNA binding domains (Zinshteyn and Nishikura, 2009 ) that enable ADAR1 to bind to genomic DNA during transcription (Herbert et al., 1998; Schwartz et al., 1999; Herbert 2019) . Additionally, ADAR1 was recently shown to be capable of mutating DNA within DNA:RNA hybrids (R-loops; Zheng, Lorenzo and Beal, 2017) . We therefore asked whether we could identify ADAR-mediated mutations, using principles derived from mechanistic knowledge of how ADAR1 could target DNA ( Fig. 2A) :
specifically, we hypothesized that any ADAR1 editing on DNA would happen within R-loops where the RNA itself would be a canonical target of the ADAR1, so that A-to-I editing on the transcript could also generate A-to-I (hypoxanthine) mutations in the transcribed (-) DNA strand, which we would then identify as a T-to-C mutation on the reference (+) strand (or as a T-to-N mutation, in case DNA repair has failed to properly correct the hypoxanthine on the negative strand).
Based on what is known regarding other deaminases (e.g. the APOBEC family; Saraconi et al., 2014), we would expect that mutations would happen at a rate that is substantially lower than the rate of the editing event (for example, APOBEC1 mutates DNA at a rate of 1 in 10,000 bp per population doubling, but can edit cognate RNA at rates approaching 100% for some transcripts). We therefore reasoned that should editing-associated mutational events exist, they would be most prominent in the context of relapse. We thus focused our analysis on 23 patient samples from the COMPASS database, for whom matched genomic (WGS) and transcriptomic (RNAseq) data were available for at least two timepoints (TP1 and TP2, pre-and post-relapse respectively) ( Fig. 2B) . We then asked whether we could correlate RNA editing (in transcripts in TP1) with DNA mutation (in genomic DNA, in TP2). Specifically, we focused on positions of A-to-I editing within a transcript at diagnosis, and compared those to instances of A-to-G mutation on the transcribed (-) strand of the cognate gene at relapse (read as T-to-C or more generally, T-to-N mutations on the + strand), within a 41bp window centered on the edited base (editing-tomutation matches) ( Fig. 2B) . Within the 23-patient cohort, we ranked the genes with RNA editing shared by at least 25% of the patients according to the number of mutations within the editing wndows. Among the top-50 genes in this list, we found a number of cancer-related new targets of RNA editing that include Mdm4 and Eif2ak2. Mdm4 encodes a well-known TP53 inhibitor (Danovi et al., 2004) . Eif2ak2 encodes Protein kinase regulated by RNA or PKR, an interferon stimulated gene (ISG) that plays a central and well-established role in the response against RNA viruses: its activation by dsRNA leads to translational shutdown (Alisi et al., 2005) . PKR also plays a crucial role in tumor suppression through interaction with p53 (Yoon, et al., 2010) . Both these transcripts have been reported as edited in the RADAR and REDIportal databases in the past (Ramaswami and Li, 2013; Picardi et al., 2016) , supporting our finding that they are indeed targets of ADAR1, however their editing has not been previously correlated with tumor progression. More importantly, we observed a concurrence between RNA editing (pre-relapse) and the emergence of DNA mutation (post-relapse), with Eif2ak2 (PKR) being the top shared target of post-relapse mutation this cohort (Fig. 2C) . The DNA mutations we identified are mostly found in 3'UTRs, where ADAR1 typically edits within Alu repeats ( Fig. 2D) . Additional cohort-and target-wise pathway enrichment analysis showed enrichment in signaling pathways associated with apoptosis and tumorigenesis (p53 signaling, JAK-STAT among others) ( Fig. 2E) , which suggests that ADAR1 might power disease progression by modulating the outcome of these pathways, either by editing or by mutation.
Disease progression in Multiple
Myeloma is facilitated either through elevated RNA editing activity or through ADAR1-associated DNA mutation. Due to the robust concurrence of the editing-to-mutation candidates with key components of tumorigenesis ( Fig. 2C,E) , we asked whether we could monitor the ADAR1-mediated generation of mutations (in TP2) by evaluating the abundance of editing activity (AEI) in TP1, in the 23-patient cohort. We then plotted editingto-mutation instances grouped per gene and per patient. We found a strong correlation with the patients' AEI in TP1 (R=0.66, p<10 -3 ), but not in TP2 (Fig.3A) . The strong correlation between editing-to-mutation counts and AEI in TP1 is consistent with our hypothesis that ADAR1 might induce DNA off-targets during its canonical RNA editing activity. The observation that there is no correlation between overall editing levels at relapse (AEI at TP2) and editing-to-mutation matches led us to test whether changes in AEI at different time points could be correlated to mutation levels. Indeed, we found that our cohort could be split into two subgroups: in the first, AEI decreases in TP2 (Fold Change <1); in the second, it increases ( Fig.3B ). We then asked if these two groups also differed, with regard to ADAR1-correlated mutations. Statistical analysis showed that the T-derived mutations within the TP1 editing-defined windows (±20bp) are enriched for patients whose AEI decreases in TP2 (Fisher's exact test: p<10 -3 , Odds Ratio>1, Fig. 3C , Suppl.
Tables S1-2). When the editing defined windows were extended by ±100bp, the same analysis showed that the T-derived mutations within the defined windows continue to be significantly enriched for the patients whose AEI decreases (p-val<2.2x10 -16 , Odds Ratio >1) compared those with AEI increase (p=10 -2 , Odds Ratio >1) in TP2 ( Fig. 3C, Suppl . Tables S1-2).
A few examples of such T-derived unique mutations upon relapse found within the editing-defined windows are provided in Fig. 3D ). One broad interpretation of these findings is the possibility that, upon the introduction of an ADAR-catalyzed driver mutation, a tumor loses its need for whatever benefit RNA editing provides to tumor evolution. Mechanistically, the driver mutation may functionally disrupt ADAR1 targeting on the transcript (e.g. by altering its structure, or the occupancy of RNA binding proteins), thus introducing an additional variable to disease progression. Accordingly, ADAR1 may facilitate tumor adaptation either through the introduction of mutations or through an increase of ADAR editing activity on the mRNA.
DISCUSSION
Multiple myeloma aggressiveness and progression has long been associated with a specific chromosomal translocation (1q21). This is also the location of the gene Adar1, which encodes a key RNA editing enzyme that is of emerging relevance to disease progression.
Consequently, a number of laboratories have studied the role of ADAR1 mediated RNA editing in MM, establishing editing as a key prognostic indicator (Lazzari et al., 2017; Teoh et al., 2018 and Fig 1) . Here we have focused specifically on the role of ADAR1 mediated deamination in the context of MM disease progression. For this, we curated a group of patients for whom we had access to good quality RNAseq and WES data during two timepoints (pre and post relapse or treatment). A comparative analysis of editing in these matched datasets defined new targets of ADAR1 editing (e.g. the transcripts that encode PKR and MDM4) with potential functional consequences for disease progression.
More importantly, our analyses of these matched datasets revealed a concurrence between editing and the acquisition of new mutations at genes whose cognate transcripts are edited, and at specific predetermined locations surrounding the site-to-be-edited. Such locations are defined by the edited adenosine within a transient RNA:DNA hybrid (an R-loop) with an average size range of ~80bp-300bp - (Chen et al., 2019; Malig et al., 2019; Stolz et al., 2019) direct DNA A-to-I deamination would then be centered around the deoxyadenosine whose riboadenosine counterpart is edited in mRNA (e.g. an adenosine in the 3'UTR), converting it to deoxyinosine (hypoxanthine). This process would contribute to T-to-C mutations (when read from the non-transcribed (+) strand) ( Fig. 3 ). Currently these data remain correlative, but do suggest a way forward to experimental validation: specifically, they imply that guide-based re-targeting of endogenous RNA editors to specific genomic locations (Qu et al., 2019) has the capacity to generate specific mutational signatures at predetermined locations. We are currently exploring this possibility.
Overall, our data suggest that the RNA editing enzyme ADAR1 is likely to function as a DNA mutator during multiple myeloma (MM) progression (Fig. 3E ). Our findings are coherent with recent analyses suggesting potential contributions of ADAR1 mediated T-to-C mutation at variable regions of antibody genes, through direct DNA A-to-I deamination at transcription bubbles The ADAR1-attributed mutations we identified in TP2 that matched editing events defined locations in TP1 occurred at a reasonably high frequency (5% of the tumor, on average). However, they remain subclonal, since in a few cases TP2 was a timepoint in which the patients were sequenced for a post-treatment check. It is possible that at later time-points these subclonal mutations would confer a selection advantage (especially as they are present in genes key to MM progression - Fig. 3) . At the same time, while it is known that APOBECs (such as APOBEC1 and multiple APOBEC3 family members) are the source of DNA mutations in cancer (estimated to occur at the rate of ~1/10,000bp per generation (Saraconi et al., 2014) , our data imply that these mutations are not randomly distributed in the genome, but are in fact centered on the genes whose transcripts are targets of the RNA editing activity of the relevant APOBEC enzyme.
Overall, our data suggest that the dual role of RNA editor and DNA mutator might be shared by many deaminases, so that DNA mutation might be the result of collateral damage on the genome by an editing enzyme, whose primary job is to re-code the cognate transcript toward specific functional outcomes. Li et al., 2009 ). RNA-seq unmapped reads were realigned to include hyperedited reads as preciously described (Porath, Carmi and Levanon, 2014) . WES data was processed as recommended by the 'GATK Best Practices' as previously described (Laganà et al., 2018) .
METHODS
RNA-seq and WES data processing
RNA editing analyses and WES mutation calling
The REDItools suite was used to detect RNA editing sites (Picardi and Pesole, 2013; Picardi et al., 2015) . In particular, the REDItoolDenovo.py python script was employed to detect Single Nucleotide Variations (SNVs) when compared to reference genome. Only well-covered (³10 reads) and reported as statistically significant (p-value£0.05) SNVs in concordant read-pairs were considered for downstream analyses. RNA editing events were defined after genomic positions with mutations called from WES data were subtracted from the SNV genomic coordinates. Mutations were called from WES data employing Strelka2 (Kim et al., 2018) and
Vardict (Lai et al., 2016) . Mutations at any frequency, but well-covered (³10 reads), were considered for proper exclusion of any DNA signal resembled on the RNA.
For the editing-to-mutation analysis, we focused on a subset of 23 patients (Fig. 2B) that had a complete set of RNA-seq and WES for two successive timepoints (TP1 and TP2).
Downstream analysis was performed so as to match RNA editing events for each patient in the TP1 to unique mutations in TP2. The matching candidates were validated with the tool bamreadcount (https://github.com/genome/bam-readcount) and annotated with Oncotator v.1.9.9.0 (Ramos et al., 2015) .
AEI, expression/pathway analyses
Pathway enrichment analysis was performed with SLAPenrich (Iorio et al., 2018) .
Alu Editing Index (AEI) was calculated from RNAseq data using REDItools as described above for detection of RNA editing sites and in-house python scripts implementing a previously described procedure (Bazak, Levanon and Eisenberg, 2014; Paz-Yaacov et al., 2015; Roth, Levanon and Eisenberg, 2019) .
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